news
CHMP recommends dengue vaccine for children
Takeda’s novel dengue vaccine has received positive opinion from the EMA’s human medicines committee (CHMP), demonstrating the vaccine is safe for patients from four years old.
List view / Grid view
Dengue
article
Anatomy of a ‘correlate of protection’ for T-cell vaccines
The use of proprietary vaccine constructs to prime naive CD8+ T-cells via skin dendritic cells and thus enable induction of targeted cellular immunity, establishing tissue-resident CD8+ T-memory cells, is a new vaccination strategy being explored at Emergex Vaccines. Here, Professor Thomas Rademacher, Emeritus Professor of Molecular Medicine – UCL and…
news
EMA accepts regulatory submission for Takeda’s dengue vaccine candidate
The submission is the first in a series that will include dengue-endemic countries, it includes long-term Phase III safety and efficacy data for the TAK-003 vaccine candidate.
news
New partnership to explore potential biodefence applications for FX-06
Under a licensing and collaboration agreement, Partner Therapeutics will evaluate whether FX-06 could be used to treat multiple biothreats of interest to the US Government.
news
Novel HIV vaccine approach shows promise in “landmark” first-in-human trial
The vaccine was able to target the desired immune cells and could become the first stage of a multi-step vaccine strategy to combat HIV and various other viral diseases.
news
Philippines may re-introduce controversial dengue vaccine
The Philippines is considering re-introducing a dengue vaccine whose use was ceased because of links to several deaths.
article
Climate change: how pharma will profit from a warming planet
Rising temperatures will likely accelerate the spread of vector-borne diseases, resulting in an increased demand for vaccines. European Pharmaceutical Review investigates a Morgan Stanley report on the pharmaceutical beneficiaries of climate change.
news
Integrated lab-on-a-chip uses smartphone to detect multiple pathogens
Researchers have developed a platform to diagnose infectious diseases at the point-of-care, using a smartphone as the detection instrument...
news
Sanofi sends half a million dengue vaccines to high risk Brazilians
15 August 2016 | By Sanofi
Results of the study affirm the vaccine's consistent efficacy in reducing dengue in two-thirds of the study participants, aged 9 and older. It also documents the ability of the vaccine to prevent 8 out of 10 hospitalisations and up to 93% of severe dengue cases in this age group during…
news
World’s first public dengue immunisation programme starts
5 April 2016 | By Victoria White
Dengvaxia vaccinations of one million students from 6,000 public schools in the Philippines are to begin this year...
news
Sanofi Pasteur’s Dengvaxia approved in Brazil
Dengvaxia was shown to reduce dengue due to all four serotypes in two-thirds of the participants in clinical trials and prevent 8 out of 10 hospitalisations due to dengue and up to 93% of severe dengue cases...
news
Sanofi Pasteur’s Dengvaxia approved in the Philippines
Dengvaxia is the first vaccine licensed for the prevention of dengue in the world...
